BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16091382)

  • 1. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
    Pilzer D; Fishelson Z
    Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
    Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
    J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
    Pilzer D; Saar M; Koya K; Fishelson Z
    Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.
    Reiter Y; Ciobotariu A; Jones J; Morgan BP; Fishelson Z
    J Immunol; 1995 Aug; 155(4):2203-10. PubMed ID: 7636268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
    Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
    Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emission of membrane vesicles: roles in complement resistance, immunity and cancer.
    Pilzer D; Gasser O; Moskovich O; Schifferli JA; Fishelson Z
    Springer Semin Immunopathol; 2005 Nov; 27(3):375-87. PubMed ID: 16189651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
    Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
    Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
    Brannen CL; Sodetz JM
    Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
    Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
    Morgan BP; Imagawa DK; Dankert JR; Ramm LE
    J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
    Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
    J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane vesiculation protects erythrocytes from destruction by complement.
    Iida K; Whitlow MB; Nussenzweig V
    J Immunol; 1991 Oct; 147(8):2638-42. PubMed ID: 1918984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanism of acquired resistance to complement-mediated lysis by Entamoeba histolytica.
    Gutiérrez-Kobeh L; Cabrera N; Pérez-Montfort R
    J Parasitol; 1997 Apr; 83(2):234-41. PubMed ID: 9105303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement resistance in Borrelia burgdorferi strain 297: outer membrane proteins prevent MAC formation at lysis susceptible sites.
    Patarakul K; Cole MF; Hughes CA
    Microb Pathog; 1999 Jul; 27(1):25-41. PubMed ID: 10371707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin.
    Mizukoshi E; Suzuki M; Loupatov A; Uruno T; Hayashi H; Misono T; Kaul SC; Wadhwa R; Imamura T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):461-6. PubMed ID: 10510314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
    Gancz D; Donin N; Fishelson Z
    Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
    Kontermann R; Deppisch R; Rauterberg EW
    Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.
    Reiter Y; Ciobotariu A; Fishelson Z
    Eur J Immunol; 1992 May; 22(5):1207-13. PubMed ID: 1577063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis.
    Bohana-Kashtan O; Pinna LA; Fishelson Z
    Eur J Immunol; 2005 Jun; 35(6):1939-48. PubMed ID: 15902683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
    Hänsch GM; Schönermark S; Roelcke D
    J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.